To determine the long term efficacy of aspirin and oral anticoagulants in reducing ischemic events after acute coronary events.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Anticoagulants Drug
Prospective, multicenter, randomized open-label trial.
Patients were randomized into 3 groups to receive either aspirin (80 mg) (n=336), oral anticoagulants (target INR 3.0-4.0) (n=325) or oral anticoagulants (target INR 2.0-2.50 plus aspirin (80 mg) (n=332). An assessment questionnaire was completed every 3 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Death, time to myocardial infarction or stroke.|
|Secondary||Death from all causes, episodes of bleeding.|